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Background: There is limited population-based literature on rates and risk factors for revision following primary total hip
replacement.
Methods: We performed a retrospective cohort study of Medicare beneficiaries who had elective total hip replacement for
osteoarthritis between July 1, 1995, and June 30, 1996. Patients were followed with use of Medicare claims through 2008. The
primary end point was revision total hip replacement as indicated by hospital discharge codes according to the International
Classification of Diseases, Ninth Revision. We used the Kaplan-Meier method to plot the risks of revision and of death over a
twelve-year follow-up period. We used Cox proportional hazard regression models to identify preoperative risk factors for revision
of primary total hip replacement. We conducted sensitivity analyses to account for competing risks of major comorbid conditions.
Results: The risk of revision total hip replacement for patients remaining alive was approximately 2% per year for the first
eighteen months and then 1% per year for the remainder of the follow-up period. The absolute risk of death over the twelve-
year follow-up period exceeded the risk of revision total hip replacement by a factor of ten (59% vs. 5.7%) in patients older
than seventy-five years at the time of primary total hip replacement and by a factor of three (29% vs. 9.4%) in patients sixty-
five to seventy-five years old at the time of surgery. In multivariate Cox proportional hazard models, the relative risk of
revision was higher in men than in women (hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 1.15, 1.31) and in
patients sixty-five to seventy-five years of age at the time of primary total hip replacement than in those over seventy-five
years (HR, 1.47; 95% CI, 1.37, 1.58). Patients of surgeons who performed fewer than six total hip replacements annually
in the Medicare population had a higher risk of revision than those whose surgeons performed more than twelve per year
(HR, 1.21; 95% CI, 1.12, 1.32).
Conclusions: Efforts to reduce the number of revision hip arthroplasties should be targeted at revisions occurring in the
first eighteen months following the index arthroplasty, when revision risk is higher, and at younger patients, who are more
likely to survive long enough to require revision.
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otal hip replacement is performed on more than
280,000 persons annually in the United States1. For
more than 90% of these procedures, the underlying
diagnosis is osteoarthritis of the hip. While the results of total
hip replacement are generally excellent, implant failure may
occur by a number of mechanisms, including infection, dis-
location, and osteolysis leading to symptomatic loosening.
Patients with symptomatic failure of a primary total hip
replacement are typically referred to orthopaedic surgeons for
consideration of revision surgery. Revision total hip replace-
ment is performed on more than 40,000 persons annually in
the U.S., at a direct cost exceeding $1 billion1.
Study of the risk of revision total hip replacement among
patients having primary surgery and of factors associated with
revision risk is challenging. Because revision is a relatively
infrequent outcome that can occur a decade or more after
the primary surgery, such studies must involve large cohorts
of patients followed consistently over many years. To our
knowledge, there are no prior population-based estimates of
the risk of revision and predictors of revision risk following
primary total hip replacement with complete follow-up ex-
tending over twelve years in the U.S. The Scandinavian hip
registries provide estimates of revision risk and risk factors for
revision. However, many of the patients entered into these large
cohorts have not been followed long enough to permit precise
estimates of long-term revision risk2–6.
Prior studies have identified male sex, younger age, and
greater activity level as risk factors associated with revision of a
primary total hip replacement7. Additional risk factors are as-
sociated with specific indications for revisions such as dislo-
cation and infection8,9. Lower surgeon volume has been
associated with higher revision risk in the first eighteen months
after primary total hip replacement, with no further risk as-
sociated with surgeon volume from eighteen months to four
years10. The association of surgeon volume with longer-term
risk of revision for more than four years after total hip re-
placement has not been examined. Prior studies of revision
total hip replacement have not placed revision risk in the
context of the considerable mortality that patients experience
in their seventh through ninth decades of life.
The objectives of this study were to address these research
gaps by examining the risk of revision following primary total
hip replacement for osteoarthritis in the U.S. Medicare pop-
ulation and to examine the effects of sociodemographic fac-
tors and surgeon and hospital volume on the risk of revision
over a twelve-year period of follow-up. We also placed the ab-
solute risk of revision after primary total hip replacement among
patients who were more than sixty-five years old at the time of
surgery in the context of patient mortality in this age group.
Materials and Methods
We performed a retrospective claims-based cohort study of revision fol-lowing primary total hip replacement in the U.S. Medicare population.
The sample included Medicare beneficiaries who had primary elective total hip
replacement for osteoarthritis from July 1, 1995, through June 30, 1996. On the
basis of coded diagnoses and procedures in the total hip replacement hospitali-
zation, we excluded patients with other underlying diagnoses. We also excluded
patients enrolled in a Medicare health maintenance organization, as submission
of claims is inconsistent in this group. We described this cohort in detail in prior
work
10,11
. Because this is a claims-based cohort study, subjects are identified and
followed longitudinally solely with claims data.
We followed patients in claims through December 31, 2008. The pri-
mary outcome was revision total hip replacement identified with use of In-
ternational Classification of Diseases, Ninth Revision (ICD-9) codes at hospital
discharge. The code for revision was 81.53 prior to September 30, 2005, and
00.70 to 00.73 subsequently. We recognized that revisions on the right and left
side cannot be distinguished in Medicare claims
12
. Therefore, if subjects had a
primary total hip replacement on the contralateral side after the index primary
procedure, we censored the subject at the time of the subsequent primary
procedure because a revision following these two primary total hip replace-
ments could not reliably be attributed to the index total hip replacement. We
could not exclude patients with a total hip replacement on the contralateral side
prior to the index primary procedure or prior to sixty-five years of age because
we did not have claims data for years prior to 1995 and because patients do not
enter Medicare coverage until they are sixty-five years old.
We used the Kaplan-Meier method to estimate and depict graphically
the cumulative revision risk, stratified by the age of the patient at the time of
surgery, sex of the patient, and annual volume of total hip replacements per-
formed by the surgeon. We depicted the Kaplan-Meier estimates in two ways.
First, per convention, for each month of the follow-up period, we plotted the
proportion of patients free of revision among those who were alive at the start of
the month. The second approach captured the competing risk of mortality in
this aging cohort. At the month of follow-up, we graphed the proportions of
patients who were alive and revision-free, those who had died without revision,
and those (either dead or alive) who had had a revision.
We examined risk factors for revision of primary total hip replacement
using a Cox proportional hazards model. The dependent variable in the model
was time to revision total hip replacement over the twelve-year follow-up pe-
riod. Independent variables were ascertained at the time of total hip replace-
ment and included patient age, sex, race, Medicaid eligibility (proxy for low
income), and comorbidity, as well as hospital and surgeon annual volume of
total hip replacements in the Medicare population. We dichotomized age as
sixty-five to seventy-five years or as more than seventy-five years and race as
white or nonwhite. Comorbidity was assessed with the claims-based Charlson
comorbidity index and was dichotomized as zero or one comorbidity versus
two or more
13,14
. Hospital and surgeon volume were calculated from claims and
comprised the annual volume of primary total hip replacements performed by
the hospital (or surgeon) on Medicare beneficiaries from July 1995 through
June 1996. On the basis of prior work
11,15
, we categorized hospital volume as
one to twenty-five, twenty-six to fifty, and more than fifty total hip replace-
ments per year in the Medicare population. Similarly, surgeon volume was
categorized as less than six, six to twelve, and more than twelve total hip
replacements per year in the Medicare population. We used the piecewise
exponential model to estimate the effects of surgeon volume on risk of re-
vision total hip replacement in different time periods: the first eighteen
months postoperatively, eighteen months to nine years, and nine or more
years postoperatively.
We performed a sensitivity analysis to account for competing risks in
patients with total hip replacement. Competing risks occur when the patient
may experience outcomes that alter or prevent the primary outcome of revision
total hip replacement from occurring
16,17
. For example, if a patient has a stroke
and becomes less mobile, a revision may be delayed or never undertaken. Our
sensitivity analysis considered death, fracture, stroke, and myocardial infarc-
tion, identified in Medicare claims, as competing risks for revision. Potential
predictors of revision were evaluated with use of a proportional hazards model
for the cumulative incidence of revision adjusting for competing risks
18
. Pa-
tients were censored at the end of follow-up, twelve years, or when they received
a second primary total hip replacement.
Analyses were performed with use of SAS software (version 9.2; SAS
Institute, Cary, North Carolina) and R version 2.11.1. All study activities were
1826
TH E J O U R N A L O F B O N E & JO I N T SU R G E RY d J B J S . O R G
VO LU M E 94-A d NU M B E R 20 d OC T O B E R 17, 2012
TW E LV E -YE A R RI S K O F RE V I S I O N A F T E R P R I M A RY TO TA L HI P
RE P L AC E M E N T I N T H E U.S. ME D I C A R E PO P U L AT I O N
approved by the Human Studies Committee at Partners HealthCare and through
Data Use Agreements with the Centers for Medicare and Medicaid Research.
Source of Funding
This study was funded by the National Institutes of Health (NIH). The NIH
played no role in our investigation beyond providing the funding.
Results
Cohort Characteristics
During the study period, 76,627 patients on Medicare un-derwent total hip replacement. Of these, 51,347 met the
eligibility criteria for this study and were included in the
analysis. Baseline features of the cohort are shown in Table I.
The risk of revision arthroplasty over the follow-up period
is illustrated with Kaplan-Meier curves (Figs. 1-A and 1-B).
These figures demonstrate graphically the early incidence of
revision of approximately 2% over the first eighteen months
and then the steady occurrence of revision (at a lower rate of
approximately 1% per year) over the subsequent decade. The
figures also demonstrate the effects of patient age and sex and
surgeon volume. In analyses that considered separately the
effects of surgeon volume in the first three time periods eval-
uated, lower surgeon volume was associated with a greater
hazard of revision in the first eighteen months, but not in the
subsequent two periods.
The risks of revision arthroplasty compared with the
mortality risks over the period of follow-up are illustrated in
Figures 2-A and 2-B. As the figures demonstrate, among pa-
tients greater than seventy-five years old, 59% died within the
twelve-year follow-up window. Another 5.7% had a revision,
and 35% were alive and at risk for revision. Among patients
who were sixty-five to seventy-five years old at the time of the
primary total hip replacement, 29% died within the twelve-year
follow-up period, while another 9.4% had a revision and 62%
were alive and at risk for revision.
Bivariate Analyses of Revision Risk
We performed bivariate Cox proportional hazards models with
time to revision as the dependent variable. Separate models
were created for each potential predictor. Younger patient age,
male sex, and surgeon volume of fewer than six total hip
TABLE I Baseline Features of Study Cohort of 51,347 Medicare Beneficiaries Undergoing Primary Total Hip Replacement from July 1995
through June 1996




Age at time of primary total hip replacement
65-75 yr 30,895 60










Annual volume of total hip replacements done at hospital where




Annual volume of total hip replacements done by surgeon




*Data on race were missing for 453 patients (0.9%), and data on surgeon volume for 2221 patients (4.3%) were missing. No data were missing for
other variables. †Listed volumes indicate only Medicare patients who had total hip replacement.
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Fig. 1-A
Fig. 1-B
Figs.1-A and 1-B Kaplan-Meier curvesshowing the risk of revision total hip replacement among surviving patients. Fig. 1-A The revision-freesurvival curve is
stratified by age at the time of primary total hip replacement (sixty-five to seventy-five years of age compared with more than seventy-five years) and sex. Fig.
1-B The revision-free survival curve is stratified by the annual volume of total hip replacements done by the surgeon who performed the primary total hip
replacement (fewer than six, six to twelve, and more than twelve primary total hip replacements per year in the Medicare population).
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Fig. 2-A
Fig. 2-B
Figs. 2-A and 2-B The proportion of patients who died over the course of follow-up (dotted area), those who had a revision (black), and those who were alive
and at risk for revision (gray). The revision group includes those who remainedalive and those who had a revision and then died. Fig. 2-A Among patients who
were sixty-five to seventy-five years old at the time of primary total hip replacement, the revised group comprised 9.4% of the original cohort; 29% had died.
Fig. 2-B Among patients who were more than seventy-five years old at the time of primary total hip replacement, the revised group (black) comprised 5.7% of
the original cohort; 59% had died.
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replacements per year in the Medicare population were all as-
sociated with higher revision rates, with hazard ratios for these
factors of ‡1.24 (Table II). Hospital volume of fewer than
twenty-five total hip replacements per year (compared with
more than fifty procedures) had a hazard ratio (HR) of 1.14 (95%
confidence interval [95% CI], 1.07, 1.23). All other variables were
not significantly associated with revision total hip replacement,
with hazard ratios between 0.90 and 1.02, indicating <10% rel-
ative change in risk across levels of the variable.
Multivariate Analyses of Revision Risk
Multivariate analyses included all of the independent variables
listed in Table I (patient age, sex, race, Medicaid eligibility, and
comorbidity and hospital and surgeon volume). The results of
these analyses (Table II) showed that younger patient age
(sixty-five to seventy-five years [HR, 1.47; 95% CI, 1.37, 1.58)
was associated independently with increased revision risk after
adjusting for all other variables, as was male sex (HR, 1.23; 95%
CI, 1.15, 1.31) and having surgery performed by a low-volume
surgeon (fewer than six total hip replacements per year com-
pared with more than twelve per year [HR, 1.21; 95% CI, 1.12,
1.32]). We did not observe a significant interaction between the
association of surgeon volume and either patient age or sex on
the risk of revision. The hazards for the three strata of surgeon
volume differed significantly in the first eighteen months after
total hip replacement, with patients of surgeons with the lowest
volume having the greatest risk of revision (HR, 1.65; 95% CI,
1.39, 1.97). The hazards did not differ across volume strata over
subsequent follow-up.
The competing risk models confirmed the results of the
primary analysis, identifying the same principal predictors of
revision risk as the primary analysis—younger patient age,
male sex, and lower-volume surgeon. Detailed results of the
competing risk models are presented in the Appendix.
Discussion
We examined the risk of revision following a primary totalhip replacement in a cohort of 51,347 Medicare bene-
ficiaries who had elective primary total hip replacement be-
tween July 1995 and June 1996. Men had higher rates of
revision than women, and younger patients (those who were
sixty-five to seventy-five years old at the time of primary total
TABLE II Univariate and Multivariate Associations Between Baseline Variables and Risk of Revision Total Hip Replacement Among
Medicare Beneficiaries Undergoing Primary Total Hip Replacement from July 1995 through June 1996
Bivariate* Multivariate†
Variable Hazard Ratio 95% Confidence Interval Hazard Ratio 95% Confidence Interval
Sex
Male 1.26 1.18, 1.34 1.23 1.15, 1.31
Female 1.0
Age
65-75 yr 1.49 1.40, 1.60 1.47 1.37, 1.58
>75 yr 1.0
Race
White 0.90 0.79, 1.03
Nonwhite 1.0
Medicaid eligibility
Yes 0.92 0.80, 1.06
No 1.0
Comorbidity (Charlson score)
>1 1.02 0.93, 1.12
0–1 1.0
Hospital volume‡
1–25 1.14 1.07, 1.23
26–50 1.01 0.94, 1.10
>50 1.0
Surgeon volume‡
1–5 1.24 1.15, 1.34 1.21 1.12, 1.32
6–12 1.09 1.02, 1.18 1.08 1.00, 1.17
>12 1.0 1.0 –
*Hazard ratios obtained from bivariate Cox proportional hazards models. †Hazard ratios obtained from multivariate Cox proportional hazards
model. N = 49,136 for the multivariate model. ‡Listed volumes indicate only Medicare patients who had total hip replacement.
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hip replacement) had a higher rate than older patients. The risk
of dying over the twelve-year follow-up period far exceeded the
risk of revision, especially among the cohort of patients over
seventy-five years old at the time of primary total hip re-
placement, for whom the risk of death over the twelve-year
follow-up was tenfold greater than the risk of revision.
Our data are consistent with other literature showing an
increasing risk of revision associated with younger age and with
male sex2,7,19. Also, as we showed previously, the risk of revision
was highest in the first eighteen months after surgery, likely
reflecting early technical failures10. The influence of surgeon
volume on the risk of revision occurs in the first eighteen
months postoperatively and not thereafter, suggesting that
surgeon experience influences the risk of technical failure
but not the risk of failure over the longer term, which likely
reflects intrinsic limitations in implant durability. The asso-
ciation of surgeon volume with early failures is similar for
younger and older patients, and for men and women. We note
that the surgeon volumes in the present report reflect pro-
cedures performed in Medicare beneficiaries. Approximately
two-thirds of primary total hip replacements are performed in
Medicare recipients, and the other third in patients less than
sixty-five years old1. Thus, the Medicare volumes reported in
this paper can be multiplied by 1.5 to provide a rough estimate
of total volumes for the average surgeon. This simplification
may not be valid for particular surgeons. Because older patients
are at high risk of morbidity and mortality, competing risks may
distort estimates of revision risk. We performed analyses that
took competing risks into account; these sensitivity analyses
largely confirmed the findings of the primary analyses.
The consistent differences in failure rates seen between
younger and older patients and between men and women (Fig.
1-A) raise the question of whether shorter follow-up periods
could be used to assess differences in implant performance
rather than the longer (twelve-year) periods of observation
utilized in this study. Such a strategy would be less resource-
intensive than twelve-year follow-up. This idea cannot be ad-
dressed directly by our study and merits further investigation.
However, since surgeon practices may influence early failures,
while implant and patient characteristics influence the later ones,
this strategy may not capture risk profiles over time accurately.
The study has important limitations. First, ICD-9 coding
does not distinguish between right and left-sided procedures.
Up to 30% of the revisions that occur following primary total
hip replacement are performed on the contralateral side, even
with censoring of patients who had a second primary total hip
replacement during the follow-up period12. The likelihood that
the revision is performed on the index compared with the
contralateral hip is not influenced by patient age or sex or
surgeon volume, the three factors associated with revision risk
in this analysis12. However, the revision risks shown in Figures
1 and 2 may be overstated by as much as 30%, and the mis-
classification may have blunted the associations we observed.
Further, censoring the data on patients who had a contralateral
primary total hip replacement over the period of follow-up
may have inadvertently undercounted some bona fide revisions
of the index hip. The more general point is that administrative
data contain relatively little clinical information, and ICD-9
coding does not convey nuanced clinical information perfectly.
These issues create important limitations in the inferences that
can be derived from studies that are based on administrative
data. Thus, our findings must be confirmed in studies that
retain the national scope of this analysis but overcome the
ambiguities of administrative data.
Second, revision arthroplasty is an ambiguous proxy for
total hip replacement failure. Revision requires that surgery be
offered to and accepted by the patient. Some patients with
symptomatic loosening of the prosthesis may be too sick or frail
to undergo surgery, others may simply not present for care, and
still others may be offered revision total hip replacement but
prefer not to undergo the surgery. Consequently, actual rates of
symptomatic failure of total hip replacement are likely to be
higher than observed revision rates.
Third, while the length of follow-up is a strength of this
study, it also means that the index procedures were done in the
mid-1990s. Implant technology, surgical technique, and reha-
bilitation practice have evolved over the subsequent years. It is
conceivable that the associations between covariates and revi-
sion documented in these analyses may have been altered be-
cause of changes in implant technology and the process of care
occurring over the last fifteen years.
The observation that patients over seventy-five years of age
undergoing primary total hip replacement face a tenfold higher
risk of death than of revision over the subsequent twelve years has
important implications for patient decision-making, quality im-
provement, and research. From a decision-making standpoint,
these older patients should place revision risk in perspective as
they discuss the advantages and drawbacks of total hip replacement
with their physicians. Because they face a 60% risk of death over
the next twelve years, their absolute risk of revision is just 6%.
Patients in the sixty-five to seventy-five-year-old group face a
somewhat higher absolute risk of revision—approximately
10%. By extension, patients less than sixty-five years old (and
especially those in their fifties) face still higher absolute risks
of revision over a ten to twenty-year time frame.
The observation that patients who have total hip re-
placement after the age of sixty-five years are much more likely
to die than to have a revision total hip replacement points to the
importance of optimizing short-term outcomes of total hip
replacement in the elderly, such as complications and resto-
ration of function. Long-term survival data on implants, as can
potentially be obtained by longitudinal joint replacement reg-
istries, will be of particular value in assessing and optimizing
the outcomes of younger patients who are much more likely to
live long enough to face possible revision surgery.
Further study of the predictors of revision in younger
patients would provide a more quantitative assessment of these
trade-offs and should be a research priority. These observations
also impact the optimal frequency with which to monitor pa-
tients with radiographs following surgery. Finally, our findings
suggest that the development of innovative technologies to im-
prove implant longevity should target younger populations with
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advanced arthritis, who have a longer anticipated time span in
which the implants might fail and require revision arthroplasty.
Appendix
Tables showing the incidence and average time for each
event type and the results from models adjusting for
competing risk are available with the online version of this
article as a data supplement at jbjs.org. n
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